[427] RESTORING GLYCEMIC CONTROL IN PATIENTS WITH T2D.

Boaz Behar, CEO, Digma Medical, Petach Tikva, Israel
Digma Medical

- **Investment Rational**
  Digma has developed a device-based, one-time, minimally-invasive procedure, that restores the body’s natural ability to control glucose, which may provide long term remission from Type-2 Diabetes & Metabolic syndrome.

- **Business Strategy**
  The Duodenal Glycemic Control procedure is unique, innovative and has no predicate device, therefore Digma is contemplating a PMA path to market. The company plans to initially approve the product for marketing in the United States, and then in the Europe and the rest of the world.

- **Core Technology**
  Type 2 Diabetes and other metabolic diseases are associated with diminishing capacity of the body to control glucose levels. Duodenal Glycemic Control™ is a safe, 30-60 minutes, minimally-invasive therapeutic procedure that uses the DiaGone™ device. DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum to restore the body’s natural ability to control glucose.

- **Product Profile/Pipeline**
  Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of our patented technology, DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. DiaGone™ is now in FIH multi-center clinical study in Spain, Israel and the Czech Republic.

- **What’s Next?**
  In the coming 18 months Digma plans to get ready for a PMA study in the US:
  Clinical - widen diabetic treatment groups to illustrate benefit to plurality of patient populations.

  Product and quality plan to fit the FDA standards

  Preclinical GLP study

  Expand organization to US.

  Approve PMA study plan with the FDA.

  Raise funding to support PMA study end to end